IGC Pharma (IGC) Total Current Liabilities (2011 - 2026)

IGC Pharma (IGC) has reported Total Current Liabilities for 16 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 27.29% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 27.29% increase from a year earlier, with the FY2026 full-year figure at $2.9 million, up 27.29% from the prior year.
• Total Current Liabilities was $2.9 million for Q1 2026 at IGC Pharma, up from $2.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $2.9 million in Q1 2026 and troughed at $1.4 million in Q4 2022.
• A 5-year average of $2.1 million and a median of $2.1 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 52.39% in 2023 and slumped 45.97% in 2025, its largest moves.
• Over 5 years, Total Current Liabilities stood at $1.4 million in 2022, then jumped by 42.77% to $1.9 million in 2023, then soared by 37.24% to $2.7 million in 2024, then declined by 18.86% to $2.2 million in 2025, then soared by 33.26% to $2.9 million in 2026.
• The last three Total Current Liabilities figures came in at $2.9 million (Q1 2026), $2.2 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.